Results 191 to 200 of about 488,286 (382)

Cancer and Placebos [PDF]

CA: A Cancer Journal for Clinicians, 1981
openaire   +2 more sources

Spermidine reproduces the anti‐inflammatory effects of intermittent fasting and prevents urate and calcium pyrophosphate crystal‐induced inflammation

Arthritis &Rheumatology, Accepted Article.
Background Gout due to the formation of monosodium urate (MSU) crystals and calcium pyrophosphate (CPP) deposition disease are two major types of microcrystalline pathologies in adults. They are responsible for recurrent flares that rely on interleukin (IL)‐1β via activation of the NLRP3 inflammasome.
Chinh Nghia Pham, Florence Castelli, Flora Finet, Charles Leroy, Céline Chollet, Twinu Wilson Chirayath, Subhalaxmi Moitra, Mylène Zarka, Agnès Ostertag, François Brial, Christèle Combes, Augustin Latourte, Thomas Bardin, François Fenaille, Pascal Richette, Hang Korng Ea   +15 more
wiley   +1 more source

Transitioning from deceptive to nondeceptive placebo treatment to reduce pathological skin-picking. [PDF]

Discov Ment Health
Schienle A, Wilhelm J, Tanzmeister S.
europepmc   +1 more source

Placebo and placebo effects in medicine [PDF]

Journal of the Royal Society of Medicine, 2000
Michael Emmans Dean, Joseph S Conway
openaire   +2 more sources

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

Arthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Has the time come to stop using control groups in trials of psychosocial interventions? [PDF]

World Psychiatry
Cuijpers P.
europepmc   +1 more source

Sobre placebo e efeito placebo [PDF]

Revista Latinoamericana de Psicopatologia Fundamental, 2002
Mônica Teixeira, Erney Plessmann de Camargo   +1 more
openaire   +2 more sources

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis

Arthritis &Rheumatology, Accepted Article.
Objective The Phase 3 MANDARA study demonstrated non‐inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair, Bernhard Hellmich, Arnaud Bourdin, David R. W. Jayne, Florence Roufosse, Nader Khalidi, Lena Börjesson Sjö, Ying Fan, Christopher McCrae, Sofia Necander, Eva Rodríguez‐Suárez, Anat Shavit, Claire Walton, Peter A. Merkel, Michael E. Wechsler   +14 more
wiley   +1 more source

Homeopathy and placebo - Synonym, similar or different? [PDF]

, 2007
Meissner, Karin, Zimmermann-Viehoff, Frank   +1 more
core   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source